Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 110 participants.

Also called NCT03062397

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 110 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03062397
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03062397. Randomized; quadruple masking; primary purpose treatment. Start 2016-12-09 (actual); primary completion 2020-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
JPI-289 Low-dose
Intervention (Drug)
JPI-289 High-dose
Intervention (Drug)
Placebo
Lead sponsor
Jeil Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03062397
Content hash
ba439372bc263d01b74ea1047437c47ab0b4dab9dd5bee9a46a6926aeb674560